An “Omics” view of drug development

✍ Scribed by Russ B. Altman; Daniel L. Rubin; Teri E. Klein

• Publisher: John Wiley and Sons
• Year: 2004
• Tongue: English
• Weight: 62 KB
• Volume: 62
• Category: Article
• ISSN: 0272-4391
• DOI: 10.1002/ddr.10370

✦ Synopsis

Abstract

The pharmaceutical industry cannot be blamed for having a love/hate relationship with the fields of pharmacogenetics and pharmacogenomics. At the same time that pharmacogenetics and pharmacogenomics promise to save pipeline drugs by identifying subsets of the population for which they work best, they also threaten to increase the complexity of new drug applications, fragment markets, and create uncertainty for prescribers who simply do not understand or have time to master “personalized medicine.” Most importantly, the logical case for genetics‐specific drug selection and dosing is much more mature than the practical list of drugs for which outcomes are demonstrably improved. Understandably, pharmaceutical developers and regulators have been careful in creating strategies for using genetics in drug development, and only recently has the FDA begun to establish preliminary rules for pharmacogenetic testing. A growing public academic effort in pharmacogenetics and pharmacogenomics is helping flesh out the basic science underpinnings of the field, and this should combine with extensive efforts of industry to create a solid foundation for future use of genetics in drug development. Two grand challenges to accelerate our capabilities include the characterization of all human genes involved in the basic pharmacokinetics of drugs, and the detailed study of the genes and pathways associated with G‐protein‐coupled receptors and how they are affected by genetic variation. Drug Dev. Res. 62:81–85, 2004. © 2004 Wiley‐Liss, Inc.